Compare MPLX LP (MPLX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs GeneDx Holdings Corp — how do they compare? MPLX LP trades at $60.05 (market cap $61.06B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: MPLX LP is far larger — about 23.7× GeneDx Holdings Corp's market cap, and MPLX LP pays a 7.15% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MPLX | WGS | |
|---|---|---|
Market Cap | $61.06B | $2.58B |
Sector | Technology | Technology |
52-Week High | $60.51 | $167.51 |
52-Week Low | $47.80 | $34.51 |
Enterprise Value | $86.17B | $2.61B |
Dividend Yield | 7.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $59.83, up 0.27% today, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong 2025 results with $11.47B revenue and $4.91B net income, though recent quarterly EPS results have missed expectations. A $1.08 dividend is scheduled for August 2026, supporting its income appeal.
The outlook remains positive given analyst buy ratings and growth projects, but risks include rising leverage near 4x and sensitivity to energy market volatility. Earnings consistency in upcoming quarters is critical to sustaining the current valuation and distribution growth trajectory.
WGS trades at $85.87, down 0.14% on the day, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4 million, beating estimates, and achieved adjusted profitability ahead of schedule. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics, driving positive sentiment.
Outlook is cautiously optimistic due to strong analyst support (90.9% buy ratings) and revenue growth, but risks include negative net income margins, high valuation multiples, and ongoing class action lawsuits. The stock's upside potential hinges on sustained operational improvements and market expansion in genomics diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
